HMY-1 Cells
General information
Description | HMY-1 cells are a human myeloma cell line derived from a patient with multiple myeloma, a type of cancer that originates from plasma cells in the bone marrow. This cell line is utilized primarily in hematological research to study the biology and treatment of multiple myeloma. The HMY-1 cell line is characterized by its ability to produce immunoglobulins, a hallmark feature of myeloma cells. These cells retain several critical features of malignant plasma cells, including high proliferative capacity and the expression of specific markers associated with plasma cell differentiation. This makes HMY-1 cells an invaluable model for investigating the molecular mechanisms of plasma cell malignancy, including the regulation of immunoglobulin production, survival signaling pathways, and drug resistance. Research utilizing HMY-1 cells often focuses on understanding the interactions between myeloma cells and the bone marrow microenvironment, which plays a significant role in myeloma progression and resistance to therapy. These studies can include examining the effects of bone marrow stromal cells on myeloma growth and survival, as well as the impact of cytokines and other growth factors. Furthermore, HMY-1 cells are used to test the efficacy of potential therapeutic agents against multiple myeloma. They provide a platform for screening drugs that target various aspects of myeloma cell biology, such as cell cycle inhibitors, apoptosis inducers, and agents that disrupt the tumor microenvironment interactions. Overall, HMY-1 cells contribute significantly to the field of myeloma research, offering insights into the pathophysiology of the disease and aiding in the development of targeted therapies to improve treatment outcomes for patients with multiple myeloma. |
---|---|
Organism | Human |
Tissue | Skin |
Disease | Melanoma |
Metastatic site | Left inguinal lymph node |
Synonyms | HMY1 |
Characteristics
Age | 62 years |
---|---|
Gender | Male |
Morphology | Fibroblast |
Growth properties | Adherent |
Identifiers / Biosafety / Citation
Citation | HMY-1 (Cytion catalog number 305145) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Tumorigenic | Yes |
---|
Handling
Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 1.5 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 37 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | 1:2 to 1:4 |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,y
CSF1PO: 12
D13S317: 11,13
D16S539: 10
D5S818: 12
D7S820: 11,14
TH01: 6
TPOX: 11
vWA: 17,19
D3S1358: 15
D21S11: 30,32.2
D18S51: 14,17
Penta E: 17,20
Penta D: 14
D8S1179: 14
FGA: 22
D6S1043: 11,13
D2S1338: 19
D12S391: 22,24
D19S433: 14,15.2
|